The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Open accessAbstract
Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The disease has been the subject of intensive research at both the basic scientific and clinical levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas. Although patients with EGFR-mutant tumours have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clinical problem. This Review summarizes recent developments aimed at treating and ultimately curing the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The third-generation drug retains the acrylamide group and covalently binds to Cys797, but replaces the quinazoline portion of the first- and second-generation compounds with pyrimidine to promote selectivity for T790M, showing a higher affinity for T790M than WT-EGFR.119”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [119]
In the citing paper
“Mutations in EGFR occur in 10-35% of NSCLCs and confer sensitivity to the EGFR TKIs erlotinib, gefitinib, and afatinib (6).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [6]
In the citing paper
“Exon 20 insertion mutations comprise 4–10% of all EGFR mutations 27,29–32.”
From Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) · cites this paper as [30]
In the citing paper
“Indeed, while ERBB2 gene amplifications and gain-of-function EGFR mutations support the proliferation of various cancer cell types (Oh and Bang, 2020; Pao and Chmielecki, 2010), VEGFA is critical for tumor-driven neoangiogenesis (Apte et al., 2019) and TGFb promotes the establishment of a fibrotic microenvironment that is poorly permissive to access by therapeutics (Derynck et al., 2020).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Pao and Chmielecki, 2010
In the citing paper
“Over the past two decades, a number of mAbs and TKIs have been developed to target these proteins or their binding partners, and some of these molecules, including HER2-, EGFR-, and VEGFA-specific agents, have been licensed for use in a variety of oncological indications (Apte et al., 2019; Oh and Bang, 2020; Pao and Chmielecki, 2010).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Pao and Chmielecki, 2010
In the citing paper
“EGFR mutations are primarily localized within two hot spots of the kinase domains, a series of overlapping deletions in exon 19 and a leucine to arginine substitution at amino acid position 858 (L858R) [reviewed in (Pao and Chmielecki, 2010)].”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Pao and Chmielecki, 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“Approximately 2–3% of NSCLCs harbour mutations in BRAF , which encodes a signalling molecule downstream of EGF”
BackgroundJemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“Another 5% of tumours harbour translocations in anaplastic lymphoma kinase ( ALK”
Background
Flagged first, then by citations
Research works printed but not linked: 1
- Oh, I.-J. et al. in AACR–IASLC Joint Conference on Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy (Coronado, California USA, 2010).
Cited by
Sorted by citations
Items 501–600 of 1,000
Wang, T., Wu, C., Huang, K., Leu, Y., Yang, S., Chen, C., & Chen, C. (2020) · Cancers · doi:10.3390/cancers13010111 · Cited by 23
“The first generation (gefitinib and erlotinib) and second generation (afatinib) of TKIs were designed to bind to the ATP binding pocket of the EGFR kinase domain [4].”
BackgroundMolecular Markers with Predictive and Prognostic Relevance in Lung Cancer
Rose-James, A., & Sreelekha, T. T. (2012) · Lung Cancer International · doi:10.1155/2012/729532 · Cited by 23
“EGFR mutations are often found in tumors of female never smokers with adenocarcinoma [12].”
BackgroundInfluentialDiacylglycerol kinase η modulates oncogenic properties of lung cancer cells
Nakano, T., Iravani, A., Kim, M., Hozumi, Y., Lohse, M., Reichert, E. C., Crotty, T. M., Stafforini, D. M., & Topham, M. K. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1036-y · Cited by 22
“One gene that is mutated in almost 60 % of lung cancers in never smokers is EGFR [2].”
Chen, C., Wu, M.-H., Chen, Y., Yen, T.-Y., Lin, Y., Chao, S.-H., Tala, S. D., Tsai, T., Su, T., & Lee, T. (2016) · Neoplasia · doi:10.1016/j.neo.2016.02.005 · Cited by 22
“Because of technological advances during the past decade, epidermal growth factor receptor (EGFR) mutations have been identified in approximately 40% of patients with NSCLC in East Asia and 15% of Caucasians and African Americans [6, 7].”
BackgroundSilencing Aurora-A with siRNA inhibits cell proliferation in human lung adenocarcinoma cells
Zhong, N., Shi, S., Wang, Z., Wu, G., Wang, Y., Ma, Q., Wang, H., Liu, Y., & Wang, J. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3605 · Cited by 22
Huang, Z.-Q., Yang, G., Shen, T., Wang, X., Li, H., & Ren, D. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.02.055 · Cited by 22
Yamaguchi, M., Hirai, S., Sumi, T., Tanaka, Y., Tada, M., Nishii, Y., Hasegawa, T., Uchida, H., Yamada, G., Watanabe, A., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.102 · Cited by 22
“Although many of these tumors initially respondwell to EGFR tyrosine kinase inhibitors (TKIs), acquired resistance nearly always develops on average 1 year after the initiation of TKI therapy [1,2].”
Ni, S., Ye, M., & Huang, T. (2017) · Oncotarget · doi:10.18632/oncotarget.18056 · Cited by 22
“Moreover, only SHOX2 methylation was significantly higher in SCC than in AC, but P16, RASSF1A or APC methylation had a similar level in SCC and AC.”
BackgroundInfluentialLiu, Z., Jiang, L., Li, Y., Xie, B., Xie, J., Wang, Z., Zhou, X., Jiang, H., Fang, Y., Pan, H., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.019 · Cited by 22
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells
Mologni, L., Costanza, M., Sharma, G. G., Viltadi, M., Massimino, L., Citterio, S., Purgante, S., Raman, H., Pirola, A., Zucchetti, M., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.02.009 · Cited by 21
Horn, L., Gettinger, S. N., Camidge, D. R., Smit, E. F., Janjigian, Y. Y., Miller, V. A., Pao, W. J., Freiwald, M., Fan, J., Wang, B., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.08.014 · Cited by 21
Self-citationWang, X., Zeng, Z., Cai, J., Xu, P., Liang, P., Luo, Y., & Liu, A. (2021) · BMC Cancer · doi:10.1186/s12885-021-08228-2 · Cited by 21
Luo, Y., Ma, S., Sun, Y., Peng, S., Zeng, Z., Han, L., Li, S., Sun, W., Xu, J., Tian, X., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.57964 · Cited by 23
“Tumors with constitutively active EGFR mutations were reported in up to 40% cases of NSCLC in Asian populations [41].”
BackgroundUltra-specific nucleic acid testing by target-activated nucleases
Fu, J., Li, J., Chen, J., Li, Y., Liu, J., Su, X., & Shi, S. (2021) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2021.1983757 · Cited by 22
Personalised medicine in oncology: questions for the next 20 years
Blay, J., Lacombe, D. A., Meunier, F., & Stupp, R. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70156-0 · Cited by 21
Hayes, D. N., Peng, G., Pennella, E. J., Hossain, A., Carter, G. C., Muehlenbein, C. E., & Obasaju, C. K. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2014.02.016 · Cited by 21
“It is worth remembering that gender differences in lung cancer have a strong biologic association through the correlation with EGFR mutation, such that an unrecognized similar phenomenon that could be in play as well [24,25].”
BackgroundFang, S., Wu, L., Li, M., Yi, H., Gao, G., Sheng, Z., Gong, P., Ma, Y., & Cai, L. (2014) · Nanoscale · doi:10.1039/c4nr01518e · Cited by 21
Chmielecki, J., Pietanza, M. C., Aftab, D. T., Shen, R., Zhao, Z., Chen, X., Hutchinson, K. E., Viale, A. J., Kris, M. G., Stout, T. J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823c5aee · Cited by 21
Self-citationTargeted Therapies for the Treatment of Brain Metastases in Solid Tumors
Bohn, J., Pall, G., Stockhammer, G., & Steurer, M. (2016) · Targeted Oncology · doi:10.1007/s11523-015-0414-5 · Cited by 21
Rodriguez, E. F., Shabihkhani, M., Carter, J. H., & Maleki, Z. (2017) · Acta Cytologica · doi:10.1159/000477148 · Cited by 21
Liu, Y., Ni, R., Zhang, H., Miao, L., Wang, J., Jia, W., & Wang, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s114230 · Cited by 21
Ahmed, M., Carrascosa, L. G., Sina, A. A. I., Marina-Zárate, E., Korbie, D. J., Ru, K., Shiddiky, M. J. A., Mainwaring, P. N., & Trau, M. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.12.012 · Cited by 21
Zhou, T., Zhou, X., Li, P., Qi, C., & Ling, Y. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.26 · Cited by 21
“Mutations in these regions change spatial structure of the enzyme functional domain, and lead to signal activation (2).”
BackgroundTuning the specificity of DNA probes using bulge-loops for low-abundance SNV detection
Bai, S., Xu, B., Zhang, Y., Zhang, Y., Dang, H., Yang, S., Chen, Z., Zhang, L., Li, J., & Xie, G. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112092 · Cited by 21
Ducharme, G. T., LaCasse, Z., Sheth, T., Nesterova, I. V., & Nesterov, E. E. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202000108 · Cited by 20
Ding, S., Dong, X., Gao, Z., Zheng, X., Ji, J., Zhang, M., Liu, F., Wu, S., Li, M., Song, W., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105471 · Cited by 20
Acharya, B., Saha, D., Armstrong, D., Jabali, B., Hanafi, M., Herrera-Rueda, A., Lakkaniga, N. R., & Frett, B. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00457k · Cited by 21
Gao, E., Wang, Y., Fan, G., Xu, G., Wu, Z.-Y., Liu, Z.-J., Liu, J., Mao, L., Hou, X., & Li, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-60000-1 · Cited by 20
Abdelaal, N., Ragheb, M. A., Hassaneen, H. M., Elzayat, E. M., & Abdelhamid, I. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-76459-x · Cited by 23
“1A) exhibit inhibitory activity towards the Exon19 deletion 17 .”
EGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid features
Ganetzky, R. D., Finn, E., Bagchi, A., Zollo, O., Conlin, L. K., Deardorff, M. A., Harr, M. H., Simpson, M. A., McGrath, J. A., Zackai, E. H., et al. (2015) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.156 · Cited by 20
“Studies of the role of EGFR in organ and tissue development have been nearly overshadowed by the discovery of the role of activating EGFR mutations in tumor biology (Pao and Chmielecki 2010).”
BackgroundChai, S., Qian, Y., Tang, J., Liang, Z., Zhang, M., Si, J., Li, X., Huang, W., Xu, R., & Wang, K. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.10.022 · Cited by 20
RetractedClarke, N., Biscocho, J., Kwei, K. A., Davidson, J. M., Sridhar, S., Gong, X., & Pollack, J. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142061 · Cited by 20
Liu, W., Jin, F., Gao, D., Song, L., Ding, C., & Liu, H. (2017) · RSC Advances · doi:10.1039/c7ra00185a · Cited by 20
Wang, B., Li, Y.-Y., Han, J., Zhou, L.-Y., Lv, Y., Zhang, H., & Zhao, L. (2017) · Oncotarget · doi:10.18632/oncotarget.15919 · Cited by 20
“NSCLC includes adenocarcinoma (AC), squamous cell carcinoma (SCC), large cell carcinoma, and adenosquamous carcinoma [2, 3].”
BackgroundWu, S., Zhu, L., Tu, L., Sumei Chen, Huang, H., Zhang, J., Ma, S., & Zhang, S. (2018) · Radiation Research · doi:10.1667/rr14682.1 · Cited by 20
BAI1‑associated protein 2‑like 2 is a potential biomarker in lung cancer
Xu, L., Du, H., Zhang, Q., Wang, C., Li, Y., Tian, G., & Fu, X. (2018) · Oncology Reports · doi:10.3892/or.2018.6883 · Cited by 20
“Although the patients harboring EGFR mutations are more sensitive to tyrosine kinase inhibitor treatment, frequent resistance renders its clinical applications difficult for this disease (8).”
Hsin, I., Hsu, J.-C., Wu, W., Lu, H., Wu, M., & Ko, J. (2018) · Environmental Toxicology · doi:10.1002/tox.22582 · Cited by 21
“EGFR mutations are commonly observed in NSCLC, particularly lung adenocarcinoma.(2) EGFR mutation play a critical role”
Targeted Therapies in Veterinary Oncology
Londhe, P., Gutwillig, M., & London, C. A. (2019) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2019.04.005 · Cited by 20
Guo, H.-S., Xing, Y., Liu, R., Chen, S., Bian, X., Wang, F., Yang, C., & Wang, X. (2013) · Oncology Letters · doi:10.3892/ol.2013.1442 · Cited by 20
“In humans, EGFR is frequently overexpressed in 50-81% of NSCLC and such overexpression has been demonstrated to be associated with cancer susceptibility, metastasis, survival prognosis and chemotherapy response (7-14).”
Li, J., Wang, X., Hu, J. R., Shi, M. Q., Zhang, L., & Chen, H. (2019) · Cancer Medicine · doi:10.1002/cam4.2610 · Cited by 20
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20
Kinase dysfunction and kinase inhibitors
London, C. A. (2013) · Veterinary Dermatology · doi:10.1111/j.1365-3164.2012.01081.x · Cited by 19
Molecular Characterization by Immunocytochemistry of Lung Adenocarcinoma on Cytology Specimens
Moreira, A. L., & Hasanovic, A. (2012) · Acta Cytologica · doi:10.1159/000339794 · Cited by 19
Morabito, A., Costanzo, R., Rachiglio, A. M., Pasquale, R., Sandomenico, C., Franco, R., Montanino, A., Lutio, E. D., Rocco, G., & Normanno, N. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318286cc26 · Cited by 19
Oncogenic role of rab escort protein 1 through EGFR and STAT3 pathway
Yun, U.-J., Sung, J. Y., Park, S.-Y., Ye, S., Shim, J., Lee, J., Hibi, M., Bae, Y., & Kim, Y.-N. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.50 · Cited by 19
High expression of NFAT2 contributes to carboplatin resistance in lung cancer
Liu, X., Pan, C., & Luo, Z. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.104290 · Cited by 19
Chen, G., Bao, Y., Weng, Q., Zhao, Y., Lu, X., Fu, L., Chen, L., Liu, Z., Zhang, X., & Liang, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01533 · Cited by 19
“There are a series of small molecular inhibitors that can inhibit the kinase activity of EGFR had been found and named as EGFR-TKIs (Sequist et al., 2007; Pao and Chmielecki, 2010).”
BackgroundWang, J., Sun, N., Lee, Y., Ni, Y., Koochekpour, R., Zhu, Y., Tseng, H., Wang, S., Jiang, L., & Zhu, H. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00589d · Cited by 19
A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models
Singh, S. S., Mattheolabakis, G., Gu, X., Withers, S. S., Dahal, A., & Jois, S. D. S. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113312 · Cited by 19
Addressing the Right Targets in Oncology: Challenges and Alternative Approaches
Stock, J. K., Jones, N. P., Hammonds, T. R., Roffey, J., & Dillon, C. (2015) · SLAS DISCOVERY · doi:10.1177/1087057114564349 · Cited by 19
“Further clinical trials confirmed this correlation and led to the approval of these agents for the treatment of advanced EGFR-mutant NSCLC.(30) Erlotinib is now a firstline treatment for metastatic NSCLC with exon 19 deletions or exon 21 (L858R) substitution mutations.”
MethodIommelli, F., Rosa, V. D., Terlizzi, C., Monti, M., Panico, M., Fonti, R., & Vecchio, S. D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3657 · Cited by 19
“The EGFR has been recognized as a driver of non–small cell lung cancer (NSCLC) and served as a paradigm for tumor targets that can be successfully inhibited by specific tyrosine kinase inhibitors (TKI) or antagonists with a consequent clinical benefit for the patient (8).”
BackgroundFoo, J., & Leder, K. (2016) · Cited by 19
EGFR inhibitors across generations: Progress, challenges, and future directions
Deshmukh, V. G., Sapkal, S. B., Gadekar, S. S., & Deshmukh, V. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142326 · Cited by 20
Mechanism of Chinese yam for the treatment of aging-related diseases based on network pharmacology
Chen, G., Huang, C., Shi, P., Xu, H., Gao, S., Luo, D., Chen, T., Xie, Y., Huang, R., Song, H., et al. (2020) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2020.101254 · Cited by 18
Lung adenocarcinoma-related target gene prediction and drug repositioning
Huang, R., Siriwanna, D., Cho, W. C. S., Wan, T. K., Du, Y. R., Bennett, A. N., He, Q., Liu, J., Huang, X. T., & Chan, K. H. K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.936758 · Cited by 18
“For example, the epithelial growth factor receptor (EGFR) inhibitors, gefitinib, and erlotinib are already used to treat LUAD patients (Janku et al., 2010; Pao and Chmielecki, 2010).”
BackgroundGasdermin E regulates the stability and activation of EGFR in human non-small cell lung cancer cells
Xu, L., Shi, F., Wu, Y., Yao, S., Wang, Y., Jiang, X., Su, L., & Liu, X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01083-7 · Cited by 18
“EGFR is also overexpressed in NSCLC [12], and activation of EGFR signaling (EGFR gene amplification and active mutations) is a critical driving force for NSCLC (~ 85%) [10].”
BackgroundLiu, B., Gao, F., Zhao, H., Yuan, S., Peng, X., Zhang, P., Wang, J., Zhang, T., Duan, M., & Guo, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115590 · Cited by 18
ERβ Regulates NSCLC Phenotypes by Controlling Oncogenic RAS Signaling
Nikolos, F., Thomas, C. G., Rajapaksa, G. K., Bado, I. L., & Gustafsson, J.-Α. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0663 · Cited by 18
Sutiman, N., Zhang, Z., Tan, E. H., Ang, M., Tan, S.-W. D., Toh, C., Ng, Q. S., Chowbay, B., & Lim, W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154316 · Cited by 18
Yang, J., Han, F., Liu, W., Zhang, M., Huang, Y., Hao, X., JIANG, X. H., Li, Y., Chen, H., Cao, J., et al. (2017) · Journal of Cancer · doi:10.7150/jca.19972 · Cited by 18
“Among the different types of lung cancers, non-small cell lung cancer (NSCLC), primarily comprising lung adenocarcinoma and lung squamous cell carcinoma, constitutes over 80% of lung cancer patients [3, 4].”
BackgroundYang, Z., Hu, X., Zhang, S., Zhang, W., & Tam, K. Y. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.08.037 · Cited by 18
Developing an Agent-Based Drug Model to Investigate the Synergistic Effects of Drug Combinations
Gao, H., Yin, Z., Cao, Z., & Zhang, L. (2017) · Molecules · doi:10.3390/molecules22122209 · Cited by 18
“Erlotinib has activity against epidermal growth factor receptor (EGFR) with the function of inhibiting tumor proliferation and differentiation [43].”
BackgroundXu, H., Yang, G., Li, W., Li, J., Hao, X., Xing, P., Yang, Y., & Wang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.713483 · Cited by 19
Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing
Feng, H., Wang, X., Zhang, Z., Tang, C., Ye, H., Jones, L. E., Lou, F., Zhang, D., Jiang, S., Sun, H., et al. (2015) · Cancer Informatics · doi:10.4137/cin.s22941 · Cited by 19
Jiang, Z., Gu, Z., Yu, X.-M., Cheng, T., & Liu, B. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1447678 · Cited by 22
“Gene mutations in the EGFR tyrosine kinase domain can also lead to autophosphorylation of tyrosine residues, initiating downstream signaling pathways such as RAS/RAF/MEK/ERK, PI3K/AKT/ mTOR, and promoting cell proliferation and growth through cascade reactions (89 – 91).”
AS1411-functionalized delivery nanosystems for targeted cancer therapy
Kozani, P. S., Kozani, P. S., & Malik, M. T. (2021) · Exploration of Medicine · doi:10.37349/emed.2021.00039 · Cited by 18
Liu, Y., Huang, J., Wu, M., Bi, L., Lin, Q., Wu, J., Ouyang, Y., Guo, X., Huang, R., Zhang, Y., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114463 · Cited by 17
GPR87 promotes tumor cell invasion and mediates the immunogenomic landscape of lung adenocarcinoma
Bai, R., Zhang, J., He, F., Li, Y., Dai, P., Huang, Z., Han, L., Wang, Z., Gong, Y. Q., & Xie, C. (2022) · Communications Biology · doi:10.1038/s42003-022-03506-6 · Cited by 17
Takeuchi, S., & Yano, S. (2014) · Respiratory Investigation · doi:10.1016/j.resinv.2014.10.002 · Cited by 17
“Threonine, which is the 790th amino acid located in exon 20 of the EGFR, undergoes mutation to methionine, and T790M is detected in about 50% of tumors with acquired resistance [1,3,4].”
BackgroundUsing functional genomics to overcome therapeutic resistance in hematological malignancies
Calderon, F. A., Gregory, M. A., & DeGregori, J. V. (2012) · Immunologic Research · doi:10.1007/s12026-012-8353-z · Cited by 18
“Second, while many cancers develop mutations in the kinase domain of EGFR that confer resistance to EGFR small molecule inhibitors [65, 66], acquired activation of alternative signaling pathways is frequent [64, 67].”
Regulators of carcinogenesis: Emerging roles beyond their primary functions
Jia, L., Zhang, R., Shen, L., & Yang, A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.048 · Cited by 17
Toki, M. I., Carvajal‐Hausdorf, D., Altan, M., McLaughlin, J. F., Henick, B. S., Schalper, K. A., Syrigos, K. N., & Rimm, D. L. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.025 · Cited by 17
“Although not yet proved, this observation could be associated with the reported 75% response rate of EGFR-mutant patients to EGFR TKIs.(34) Additionally, the EGFR-GRB2 PLA signal was higher in EGFR-mutant and EGFR wild-type patients compared with in KRAS-mutant patients, although there were some KRAS-mutant tumors wit…”
ResultMET Amplification and Response to MET Inhibitors in Stage IV Lung Adenocarcinoma
Suryavanshi, M., Shah, A., Kumar, D., Panigrahi, M. K., Metha, A., & Batra, U. (2017) · Oncology Research and Treatment · doi:10.1159/000457801 · Cited by 17
Lee, T., Jeong, E., Min, I. J., Kim, S. Y., Kim, H.-R., & Kim, C. H. (2017) · Oncology Letters · doi:10.3892/ol.2017.6428 · Cited by 17
“Non-small cell lung cancers (NSCLCs) harboring somatic gain-of-function mutations in the EGFR tyrosine kinase domain respond well to treatment with the EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib (2,3).”
Nanoformulated Paclitaxel and AZD9291 Synergistically Eradicate non-small-cell Lung Cancers In Vivo
Wang, X.-S., Zhang, L., Li, X., Kong, D.-J., Hu, X.-C., Ding, X.-Z., Yang, J.-Q., Zhao, M.-Q., He, Y., Lam, K. S., et al. (2018) · Nanomedicine · doi:10.2217/nnm-2017-0355 · Cited by 17
Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion
Wu, S., Liu, Y., Yu, C., Yang, J. C., & Shih, J. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22647 · Cited by 18
“Age, median years (range) 67 (28-96) 44 (28-50) 70 (51-96)”
Chiang, C., Huang, H.-C., Shen, C., Luo, Y., Chen, Y., & Chiu, C. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00737-7 · Cited by 17
Zhu, J., Yang, Q., & Xu, W. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091500 · Cited by 17
“Among them is a covalent inhibition strategy that selectively inhibits the T790M mutation of EGFR, which creates a novel core skeleton using aminopyrimidine that is different from the drug skeleton design of the first-generation inhibitor based on 4-phenylaminoquinazoline [66].”
BackgroundWu, X., Sooman, L., Lennartsson, J., Bergström, S. N., Bergqvist, M., Gullbo, J., & Ekman, S. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1710 · Cited by 17
Takagi, Y., Nakahara, Y., Hosomi, Y., & Hishima, T. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-529 · Cited by 18
Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer
Politi, K. A., & Lynch, T. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3282 · Cited by 17
“Retrospective and prospective studies have established that 70% of tumors harboring these mutations respond to treatment with the EGFR tyrosine kinase inhibitors, gefitinib or erlotinib (6).”
BackgroundBorriello, A., Caldarelli, I., Bencivenga, D., Stampone, E., Perrotta, S., Oliva, A., & Ragione, F. D. (2016) · Oncotarget · doi:10.18632/oncotarget.12649 · Cited by 16
Castelli, R., Bozza, N., Cavazzoni, A., Bonelli, M. A., Vacondio, F., Ferlenghi, F., Callegari, D., Silva, C., Rivara, S., Lodola, A., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.029 · Cited by 17
Zhou, R., Liu, Z., Wu, T., Pan, X., Li, T., Miao, K., Li, Y., Hu, X., Wu, H., Hemmings, A. M., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01954-7 · Cited by 17
“The ATP-binding pocket of EGFR is a critical site for inhibitor binding, making it a primary target in drug design efforts for NSCLC [5].”
Feiner, R. C., Kemker, I., Krutzke, L., Allmendinger, E., Mandell, D. J., Sewald, N., Kochanek, S., & Müller, K. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249535 · Cited by 16
Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer
Sun, P., Qu, Y., Wang, Y., Wang, J., Wang, X., & Sheng, J. (2021) · Journal of Cancer · doi:10.7150/jca.54574 · Cited by 16
“Unfortunately, after 9-14 months of treatment, almost all patients developed drug resistance [11, 12].”
BackgroundDemehin, A. A., Thamnarak, W., Lamtha, T., Chatwichien, J., Eurtivong, C., Choowongkomon, K., Chainok, K., Ruchirawat, S., & Thasana, N. (2022) · Phytochemistry · doi:10.1016/j.phytochem.2022.113374 · Cited by 16
Tang, L. W. T., & Chan, E. C. Y. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115336 · Cited by 16
Al-Wahaibi, L. H., Hisham, M., Abou‐Zied, H. A., Hassan, H. A., Youssif, B. G. M., Bräse, S., Hayallah, A. M., & Abdel-Aziz, M. (2023) · Pharmaceuticals · doi:10.3390/ph16111522 · Cited by 16
Ayoup, M. S., Shawki, I., Abdel‐Hamid, H., Ghareeb, D. A., Masoud, A. A., Harras, M. F., El‐Atawy, M. A., Alharbi, N. S., & Ismail, M. M. F. (2024) · RSC Advances · doi:10.1039/d4ra02222j · Cited by 16
Sun, X., Chen, L., Li, Y.-Z., Li, W., Liu, G., Tu, Y., & Tang, Y. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.148 · Cited by 18
Cawthorne, C., Burrows, N., Gieling, R. G., Morrow, C. J., Forster, D. M., Gregory, J., Radigois, M., Smigova, A., Babur, M., Simpson, K., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0905 · Cited by 16
Nagarajan, S., Reddy, B. S. R., & Tsibouklis, J. (2011) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.33203 · Cited by 16
Ku, B. M., Bae, Y.-H., Koh, J., Sun, J., Lee, S.-H., Ahn, J. S., Park, K., & Ahn, M. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0350-y · Cited by 16
“EGFR tyrosine kinase inhibitors (EGFR TKIs) [3].”
Strategies to Overcome Acquired Resistances Conferred by Mutations in the Kinase Domain of Egfr
Lim, S. M., Jeong, Y., & Hong, S. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0019 · Cited by 16
Wang, T., Chen, C., Huang, K., Shih, Y.-M., & Chen, C. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.152926 · Cited by 16
Sun, P.-L., Kim, J. E., Yoo, S. B., Kim, H., Jin, Y., Jheon, S., Kim, K., Lee, C. T., & Chung, J. H. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3715-5 · Cited by 16
Zhu, H., Wu, C., Wu, T., Wen, X., Ci, S., He, W., Zhang, Y., Li, L., Zhou, S., Zhang, J., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1215 · Cited by 16
Ferrara, M. G., Martini, M., D’Argento, E., Forcella, C., Vita, E., Noia, V. D., Sperduti, I., Bilotta, M., Ribelli, M., Damiano, P., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.12.008 · Cited by 16
FAM83H‐AS1 is a noncoding oncogenic driver and therapeutic target of lung adenocarcinoma
Wang, S., Han, C., Liu, T., Ma, Z., Qiu, M., Wang, J., You, Q., Zheng, X., Xu, W., Xia, W., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.316 · Cited by 15
Metadata
- Authors
- Pao, W., & Chmielecki, J.
- Affiliations
- Vanderbilt University (US)
- Corresponding author
- Pao, William
- Venue
- Nature Reviews Cancer
- Published
- 2010-10-22
- Volume
- 10
- Issue
- 11
- Pages
- 760-774
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3072803
- OpenAlex
- W2090029719
- Cited by
- 1,083
- References
- 180
- Citations by year
- 2026: 24 · 2025: 43 · 2024: 54 · 2023: 49 · 2022: 45 · 2021: 65 · 2020: 79 · 2019: 56 · 2018: 69 · 2017: 72 · 2016: 90 · 2015: 82 · 2014: 93 · 2013: 93 · 2012: 104
- FWCI
- 14.65
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Vanderbilt University
- National Institutes of Health
- University of California, San Francisco
- National Cancer Institute (P30 CA 68485, R01CA121210, P01CA129243, CA90949, U54CA143798, P50CA090949, P30CA068485)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR-mutant non-small cell lung cancer, epidermal growth factor receptor, tyrosine kinase inhibitors, gefitinib, erlotinib, acquired drug resistance, primary resistance, targeted therapy
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Protein-Tyrosine Kinases, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
